NCT07422363 2026-03-18
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
Clinical Trials
14 trialsNCT07297160 2026-03-04
CALySSEY
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT07444619 2026-03-03
A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07443137 2026-03-02
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
Stanford University
Phase 1 Not yet recruiting
NCT07297667 2026-02-13
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Canadian Cancer Trials Group
Phase 1 Not yet recruiting
NCT07211737 2026-02-06
NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT07054944 2025-12-15
T-LyM
University of Rochester
Phase 1 Not yet recruiting
NCT07027423 2025-12-01
BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas
University Health Network, Toronto
Phase 1 Not yet recruiting
NCT07171203 2025-09-12
Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
University of California, San Diego
Phase 1 Not yet recruiting
NCT07052383 2025-07-04
Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
Tcelltech Inc.
Phase 1 Not yet recruiting
NCT06748872 2024-12-27
EPITOME-1015-I
Medigene AG
Phase 1 Not yet recruiting
NCT06699576 2024-11-21
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
Hansoh BioMedical R&D Company
Phase 1 Not yet recruiting
NCT06610071 2024-09-24
NIFR;SWIG
The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Phase 1 Not yet recruiting
NCT05361954 2023-04-12
Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
Sorrento Therapeutics, Inc.
Phase 1 Not yet recruiting